前往化源商城

175348-09-1 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: cmt-p4-fda-celltiter_regid
Protocol: Native S16 cells were seeded in white solid-bottom 1536 well plates at between 500-750 cells/6uL in DMEM medium containing 10% FBS, w/o phenol red. After overnight incubation at 37 degree Celsius/5% C02, 23 nL of compounds or DMSO were delivered to each well using a pin tool, followed by 24h-incubation at 37 degree Celsius/5% C02. Then one volume of CellTiter-Glo assay reagent (Promega) was added to each well for cell viability measured by a ViewLux plate reader (PerkinElmer). The % activity was determined by normalizing to the average readings from wells containing no cells relative to DMSO-treated cells (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, toxic compounds are ranked higher than non-toxic compounds.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Toxic compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007350000 uMActivity at 0.0008220000 uMActivity at 0.00164 uMActivity at 0.00382 uMActivity at 0.00822 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.206 uMActivity at 0.477 uMActivity at 1.030 uMActivity at 2.387 uMActivity at 5.336 uMActivity at 11.50 uMActivity at 25.70 uMActivity at 57.50 uMCompound QC
Inactive04-5.0009-3.85828.5637.7356-2.60638.8494-2.90027.3097-5.0009QC'd by "Chemical Block"
Inactive0-6.34224.95490.5937-12.668213.847440 0 0 0 0 0 0 0-1.069212.3719020.129923.1735-20.7201-28.56350-1.0692QC'd by "NIEHS"
Inactive0-6.94224.95490.5344-2.6603940 0 0 0 0 0 0 0-2.95733.5518.201815.5837-3.49380.18554.8403-11.8003-2.9573QC'd by "Bionet"
Inactive0-8.14220.70.37485.5-3.325140 0 0 0 0 0 0 07.3531-1.93763.13311.23193.911811.65780.794.15327.3531QC'd by "Microsource"
Inactive0-8.34221.1110.50428.5-8.207740 0 0 0 0 0 0 1-0.1414-5.17314.41623.99997.96518.56314.17684.9224-0.1414QC'd by "SigmaAldrich"
Cytotoxic9.074338.445721Complete curve; partial efficacy-5.04223.67720.9534-30.61847.8273-1.20 0 0 0 0 0 0 0-31.20485.95771.410115.34117.31819.36473.7902-29.5419-31.2048QC'd by "BIOMOL"
Inactive04-1.1093.12850.95515.46465.5291-22.30798.65081.0562-1.109QC'd by "BIOMOL"
Inactive0-4.64222.04370.4724-12.25234.540 0 0 0 0 0 0 0-10.2103-2.8783-1.96848.16842.652216.10652.7958-5.0963-10.2103QC'd by "Microsource"
Inactive04-35.0613-10.1978-31.4679-21.1443-10.6505-13.0426-18.8828-22.614-35.0613QC'd by "SigmaAldrich"
Inactive04-0.43678.5443-1.90230.867411.703712.903511.67040.94-0.4367QC'd by "BIOMOL"
Inactive0-8.29221.10.70078.5-4.990140 0 0 0 0 0 0 1-2.7665-2.49174.50735.70939.147311.094311.54643.6682-2.7665QC'd by "Microsource"
Inactive04-23.26811.1336-28.53635.73076.3285-1.73042.4702-11.2804-23.2681QC'd by "BIOMOL"
Inactive0-5.64224.95490.5184-0.1857740 0 0 0 0 0 0 17.08570.447811.22575.64758.42318.0861-0.98810.29837.0857QC'd by "BIOMOL"
Inactive0416.40688.443411.318421.924627.44418.887710.570822.657716.4068QC'd by "BIOMOL"
Inactive0-8.64224.95490.90670.5-21.968840 0 0 0 0 0 0 1-18.1607-18.30732.5460.7431-0.64421.9512.9894-3.7133-18.1607QC'd by "SigmaAldrich"
Inactive0-7.79224.0950.60476-4.042940 0 0 0 0 0 0 1-6.0398-4.2024-3.33235.561713.5456.78374.27220.3922-6.0398QC'd by "SigmaAldrich"
Inactive0-8.44223.24750.6851-5.60992140 0 0 0 0 0 0 0019.0978-3.8976-10.2909-16.7583-7.9421000QC'd by "BIOMOL"
Inactive048.3767-0.84056.581514.3275-0.043416.57681.30653.99668.3767QC'd by "BIOMOL"
Inactive047.7788.1853-2.3072-1.044911.73596.1253-2.342211.7587.778QC'd by "NIEHS"
Cytotoxic32.196895.472540Partial curve; high efficacy-4.49224.95490.992-92.72312.7494-2.10 0 0 0 0 0 0 0-88.30773.5692-1.34043.36762.4201-1.00816.7043-17.8812-88.3077QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1158_MLP
Protocol: A 5 mL overnight pre-culture of E. coli is started by inoculating a tube of lysogeny broth with a single colony from an agar plate. The tube is incubated at 37 degrees C overnight with shaking. The resulting saturated culture is removed from the shaker and diluted into fresh lysogeny broth at 1:100 proportion and incubated at 37 degrees C with shaking for two hours. The culture is removed from the shaker and absorbance is measured at 600 nm. The culture is diluted into fresh lysogeny broth to an estimated absorbance of 0.0002. For each library plate to be screened, two 384-well assay plates are filled with 30 microL per well of fresh lysogeny broth, except for the positive control columns, which are left empty. The multiple of two is necessary to expose the strain in duplicate to the same compounds from a given library plate.

300 nL of experimental compounds are transferred into the assay plates from library plates using a robotically manipulated stainless steel pin array, exposing the strain to the same compounds at the same concentration. The positive control columns are filled with 30 microL of the positive control compound in LB. Thirty microL of E. coli culture at absorbance of 0.0002 are then added to the assay plates, producing a total volume of 60 microL in each well. Plates are incubated at 37 degrees C without shaking and with humidification for 23 hours. The plates are removed from the incubator, and absorbance of the cultures is measured at 600 nm using a PerkinElmer EnVision plate reader. The absorbance is used as the readout.

Positive control: (R)-4-(4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide was present at 0.0754 microM in all wells of column 24.

Negative control: No treatment in remaining empty wells of the assay plate (minimally, wells in column 23).
Comment: A threshold constant was calculated by subtracting 3.6 X experimental well standard deviation for absorbance from the experimental well average absorbance, combining all plates in a screening run. Well absorbance was then subtracted from this threshold value. Wells were considered active if the resulting value after subtracting the threshold constant > 0 for at least one replicate. Activity scores were calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_AAbsorbance_BAbsorbance_AvgThreshold-Absorbance_AThreshold-Absorbance_B
0.7180.7170.7175-0.187986-0.186986
0.7320.720.726-0.201986-0.189986
0.6630.7090.686-0.132986-0.178986
0.6310.6880.6595-0.100986-0.157986
0.6840.6970.6905-0.153986-0.166986
0.7010.7060.7035-0.170986-0.175986
0.6950.6860.6905-0.164986-0.155986
0.6690.6990.684-0.138986-0.168986
0.650.7090.6795-0.119986-0.178986
0.6880.6750.6815-0.157986-0.144986
0.6770.6920.6845-0.146986-0.161986
0.660.7130.6865-0.129986-0.182986
0.6970.6830.69-0.166986-0.152986
0.6540.7120.683-0.123986-0.181986
0.6820.6840.683-0.151986-0.153986
0.6870.7060.6965-0.156986-0.175986
0.6680.6950.6815-0.137986-0.164986
0.70.7040.702-0.169986-0.173986
0.680.7030.6915-0.149986-0.172986
0.690.6870.6885-0.159986-0.156986
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1482
Protocol: Prior to screening, cells were passaged in high glucose DMEM supplemented with 10% FBS, 1% P/S, 1 mM pyruvate, and HEPES. Media was changed every 1-2 days to prevent starvation and maintain cellular health.

On the day of screening, 384-well plates (Corning 3765) were filled with 30 uL of control cybrid cell suspension (33.3 cells/ul). Media for resuspension was DMEM supplemented with 10% FBS, 1% P/S, 1 mM pyruvate, and HEPES. Positive control columns were 23 and 24 for most plate setups. Initially, tunicamycin (15 nM) and galactose media (10 mM + 1 mM glucosamine) were used in columns 23 and 24, respectively. Over the course of the screen, galactose was substituted with Vidofludimus (11 uM). Next, 33 nL of each compound were pin-transferred to each plate in duplicate. Final assay well volume was 30 uL. Plates were stacked 2 high, covered with lids, and incubated at 37 degrees C for 2 days.

After 2 days of incubation, Hoescht (10 ul/well) was added to assay plates and fluorescence was read using the Acumen laser scanning cytometer. After, the bottom of plates were sealed with two layers of Brightmax Sealing Films. Then Promega NanoGlo Live cell reagent (20 ul/well) was added to each well and luminescence was read on a PerkinElmer EnVision plate reader after 5 minute of shaking.
Comment: Data analysis method and criteria for scoring active compounds:

Normalized luminescence values (luminescence / cell number) for each replicate were calculated (based on average of 2 luminescence reads per replicate). Z-scores were calculated using the plate average and standard deviation of experimental well normalized values. Each plate replicate was individually analyzed to measure reproducibility across plates. Z-scores were then averaged across replicates and a Z-score threshold of 1.96 was selected for positive hits, indicating increased mitochondrial supercomplex formation. Wells were excluded from further consideration based on low cell number (1 or both replicates with number of objects count < 1500). Activity scores were determined by scaling Z-scores from 0 (activity score = 0) to 4 (activity score = 100), with activity score > 50 being considered active. Z-scores < 0 were set to activity score = 0; Z-scores > 4 were set to activity score = 100 (100% activity).
Luminescence_R1_ALuminescence_R2_AHoechst_NumObjects_ALuminescence_R1_BLuminescence_R2_BHoechst_NumObjects_BAvgLumin_ARatio_AAvgLumin_BRatio_BHoescht_AvgRatio_Z scoreCommentMolar Concentration
3005832966014427396274381039475429859267.447938865681.75364590.5-0.5094812 mM
3063983015303313363462354883342330396491.7489359172104.92933680.28240710 mM
3229973242934706384126370237418532364568.772837718290.1274445.5-0.3493792 mM
2814872771794410298737291541441927933363.340829513966.78864414.5-0.82501210 mM
3319403273095409320983313490473232962460.9431723667.04075070.5-0.8614472 mM
101988101433913127273124739927101710111.403126006135.929cell number censor10 mM
12229312250110001354451298281047122397122.397132636126.682cell number censor2 mM
31668831269918422981712925611315314694170.843295366224.613cell number censor10 mM
2586182572734710308202299107470525794654.765530365464.53874707.5-1.006962 mM
7032470701868774087427981170512.581.235675843.593.5185cell number censor10 mM
735767286684281944781318307322186.960880037.596.4307cell number censor2 mM
138603137684180161874155778147138144767.4641588261080.45cell number censor10 mM
3688123655174887445802425830475136716475.130943581691.73144819-0.2155272 mM
3598523457175201364558356321414235278467.830136044087.02064671.5-0.416410 mM
3539193476365169378702373151513035077867.861837592673.285149.5-0.6418412 mM
2634832564394783312776297786467925996154.35130528165.24494731-1.0023510 mM
6959871606920864718552210267060276.741385996.583.8173cell number censor2 mM
3588413473594602354858348321495635310076.727535159070.94224779-0.530435400 uM
3545733465325377378990366658522935055265.194837282471.29935303-0.71949480 uM
3160983101214700323640306279439731311066.61931496071.63054548.5-0.689973400 uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: MCF7_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, MCF7 is panel number 5, cell number 1. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
2106OS49SM1.0E-551Breast CancerMCF7BRE88.231101
2106OS49SM1.0E-551Breast CancerMCF7BRE87.1119101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.4371101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.7113101
2106OS49SM1.0E-551Breast CancerMCF7BRE97.2463101
2106OS49SM1.0E-551Breast CancerMCF7BRE90.0129101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.7031101
2106OS49SM1.0E-551Breast CancerMCF7BRE30.8539101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.2896101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.8526101
2106OS49SM1.0E-551Breast CancerMCF7BRE83.1036101
2106OS49SM1.0E-551Breast CancerMCF7BRE84.2194101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.3237101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.6034101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.6643101
2106OS52SM1.0E-551Breast CancerMCF7BRE91.2503101
2106OS52SM1.0E-551Breast CancerMCF7BRE94.8714101
2106OS52SM1.0E-551Breast CancerMCF7BRE93.7372101
2106OS52SM1.0E-551Breast CancerMCF7BRE112.6132101
2106OS52SM1.0E-551Breast CancerMCF7BRE73.375101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Luciferase [Photinus pyralis]
External ID: adst-fluc-km-fda-o1_regid
Protocol: Three microliters/well of substrate- buffer solution (0.01 mM D-Luciferin, 0.01 mM ATP, 50 mM Tris Acetate, 10 mM Mg Acetate, 0.01% Tween-20 and 0.038% BSA final concentrations) were dispensed into white solid-bottom 1536 well plates. Compounds were transferred to the plates in 23nl, and one microliter/well luciferase enzyme-buffer solution (10 nM P. pyralis luciferase and 50 mM Tris Acetate final concentrations) was dispensed yielding a final reaction volume of 4 ul/well. Luciferase luminescence was measured by a ViewLux plate reader within 5 minutes of enzyme-buffer addition. The % activity was determined by normalizing to the average readings of PTC124 (a positive control) relative to DMSO (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007600859 uMActivity at 0.00164 uMActivity at 0.00357 uMActivity at 0.00764 uMActivity at 0.016 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.084 uMActivity at 0.098 uMActivity at 0.204 uMActivity at 0.443 uMActivity at 0.601 uMActivity at 1.020 uMActivity at 2.221 uMActivity at 3.851 uMActivity at 5.200 uMActivity at 11.13 uMActivity at 24.87 uMActivity at 50.60 uMActivity at 58.59 uMActivity at 123.2 uMActivity at 215.3 uMActivity at 288.0 uMCompound QC
Inactive0-4.49220.30.51734-4.606440 0 0 0 0 0 0 01.8042-4.672-4.1025-1.8343-3.7369-2.9082-0.0276-3.27281.8042QC'd by "SIGMA"
Inactive0-4.69224.0450.3458-8.5893-0.540 0 0 0 0 0 0 1-0.1897-6.0169-0.1640.01583.9661-1.6519-0.5167-6.3245-0.1897QC'd by "SigmaAldrich"
Inactive0-5.39224.95490.3662-3.09772.540 0 0 0 0 0 0 15.4199-1.74537.36030.4620.5234.8263-1.6338-2.99815.4199QC'd by "SigmaAldrich"
Inhibitor25.5748105.300940Partial curve; partial efficacy-4.59221.17050.9883-104.96170.3392-2.20 0 0 0 0 0 0 0-79.5165-3.79981.64450.16960.25152.0913-17.2656-49.2902-79.5165QC'd by "SigmaAldrich"
Inactive0-8.74224.44950.68780-6.086140 0 0 0 0 0 0 00.6926-3.82171.16341.2592-1.31090.3214-1.0557-0.36480.6926QC'd by "Chembridge"
Inactive0-4.89224.95490.392-0.6774-5.29640 0 0 0 0 0 0 0-0.8427-4.0002-6.8367-9.83-2.0415-1.9351-6.6372-0.5645-0.8427QC'd by "SigmaAldrich"
Inactive04-1.0545-8.31926.6299-1.3001-1.36740.8591-0.8748-5.7235-1.0545QC'd by "SigmaAldrich"
Inactive0-7.04220.80.711-0.5-4.896140 0 0 0 0 0 0 00.0168-4.0026-5.3301-2.4655-2.99060.3651-2.4180.11760.0168QC'd by "SigmaAldrich"
Inactive0-7.19221.41630.8466-0.5-6.118640 0 0 0 0 0 0 00.8131-6.3489-5.3075-4.1734-1.75011.2452-2.0927-0.96380.8131QC'd by "SigmaAldrich"
Inactive0-4.49224.0950.7889-0.6645-5.329340 0 0 0 0 0 0 0-0.9704-3.9692-5.7573-4.8944-5.7829-4.2413-6.1078-3.7926-0.9704QC'd by "SigmaAldrich"
Inactive0-4.99221.64360.9036-14.27221.540 1 0 0 0 0 0 1-0.79072.64976.5965-1.43033.18260.1904-2.1374-11.4768-0.7907QC'd by "Bosche"
Inactive0-8.69224.95490.89310.5-8.982640 0 0 0 0 0 0 01.1921-6.65221.36940.67421.17880.55330.1933-1.41651.1921QC'd by "SIGMA"
Inactive0-4.54221.64360.921-23.30751.540 0 0 0 0 0 0 0-17.3396-0.19295.88891.776-1.48911.55170.2982-9.8359-17.3396QC'd by "Bosche"
Inactive0-8.29222.47290.43281.5-4.903740 0 0 0 0 0 0 01.6497-4.50310.00170.95285.2306-1.05853.9254-2.26971.6497QC'd by "BIOMOL"
Inactive0-5.24222.40640.7478-1.9233240 0 0 0 0 0 0 0-0.73890.23281.80332.31213.13752.13380.241-2.8528-0.7389QC'd by "SigmaAldrich"
Inactive0-7.79224.95490.6788-3.3068140 0 0 0 0 0 0 14.31810.77691.4337-4.839-0.5865-4.7983-2.6758-3.15854.3181QC'd by "SigmaAldrich"
Inactive041.67591.4738-1.4676-2.88370.649-1.8659-1.6878-2.32581.6759QC'd by "Tocris"
Inactive04-0.47470.1407-1.50182.6348-4.58113.188-1.30740.2134-0.4747QC'd by "SigmaAldrich"
Inactive0-8.04224.95490.45590.3114440 0 0 0 0 0 0 00.54724.15642.6823-3.07390.68322.78941.3999-0.89020.5472QC'd by "SigmaAldrich"
Inactive0-4.39224.95490.91614-3.37340 0 0 0 0 0 0 013.8005-4.4775-3.8406-1.7248-1.4762-1.9012-4.2409-4.071613.8005QC'd by "SigmaAldrich"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: IGROV1_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, IGROV1 is panel number 6, cell number 10. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
0809OS51SM1.0E-5610Ovarian CancerIGROV1OVA89.6274101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA94.0185101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA77.1805101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA76.1686101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA82.5618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA88.7561101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA83.5845101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA92.7497101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA70.9555101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA58.7306101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.6041101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA90.3839101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA110.2345101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA97.6538101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA93.7697101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA56.4618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA80.8893101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA79.078101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA-20.3008101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.0949101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:peripheral myelin protein 22 [Rattus norvegicus]
External ID: cmt-p4-fluc-fda_regid
Protocol: S16 Schwann cell PMP22 intronic element firefly luciferase assay
The FLuc-expressing S16 cells were seeded in white solid 1536-well plates at between 500-750 cells/4uL in DMEM medium containing 10% FBS, w/o phenol red. After overnight incubation at 37 degree Celsius/5% C02, 23 nL of compounds or DMSO were delivered to each well using a pin tool, followed by 24h-incubation at 37 degree Celsius/5% C02. Then 4 uL ONE-Glo luminescent substrate mix (Promega) was added to each well. Luminescence was measured on a ViewLux plate reader (Perkin Elmer). The % activity was determined by normalizing to the average readings of PTC124 (a positive control) - treated cells relative to DMSO-treated cells (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007350000 uMActivity at 0.0008220000 uMActivity at 0.00164 uMActivity at 0.00382 uMActivity at 0.00822 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.206 uMActivity at 0.477 uMActivity at 1.030 uMActivity at 2.387 uMActivity at 5.336 uMActivity at 11.50 uMActivity at 25.70 uMActivity at 57.50 uMCompound QC
Inactive047.72030.8659-2.631626.4627-3.5335.70055.6162-6.89097.7203QC'd by "Chemical Block"
Inactive0-8.09223.51170.3502-0.7805840 0 0 0 0 0 0 03.2147.70063.7655-1.8745-5.09147.2979-5.6504-1.19463.214QC'd by "NIEHS"
Activator0.5725145.54280Complete curve; high efficacy-6.24221.28760.9301135.9892-9.55361.10 0 0 0 0 0 0 116.8036-10.54143.5227-23.509434.648176.9926154.1828115.554416.8036QC'd by "Bionet"
Inactive0-6.94224.95490.8667-7.52921840 0 0 0 0 0 0 0-3.302417.306414.585221.5063-6.9554-17.5244-6.2651-1.7153-3.3024QC'd by "Microsource"
Inactive0-6.49220.90.61392.531618.540 0 0 0 0 0 0 05.163916.209519.972615.599416.4813-1.223712.1710.96565.1639QC'd by "SigmaAldrich"
Inhibitor11.423977.212162Complete curve; partial efficacy-4.94224.95490.9484-72.37674.8355-1.20 0 0 0 0 0 0 0-66.34033.8942-8.8439-0.499916.45268.36299.8573-76.8381-66.3403QC'd by "BIOMOL"
Inactive0-7.99224.95490.727413-6.972340 0 0 0 0 0 0 015.738-7.0603-1.393621.18974.47710.39715.28359.863915.738QC'd by "BIOMOL"
Inactive0-4.39224.95490.6125-10.695812.540 0 0 0 0 0 0 0-8.91328.44036.171423.02966.129917.144711.573813.1002-8.9132QC'd by "Microsource"
Inactive04-4.4526-4.0128-7.78831.7483-10.2179-16.325-24.6675-1.5165-4.4526QC'd by "SigmaAldrich"
Inhibitor16.1366111.356610Single point of activity-4.79224.95490.9134-102.9858.3716-30 0 0 0 0 0 0 1-16.77037.232426.7976-2.6004-8.50019.385517.0307-92.7972-16.7703QC'd by "BIOMOL"
Inhibitor16.136681.614141Partial curve; partial efficacy-4.79221.62590.9436-75.61416-2.20 0 0 0 0 0 0 0-70.28398.929516.981-8.24474.56678.2089-8.3819-47.4244-70.2839QC'd by "Microsource"
Inactive0-5.59224.44950.4256-9.885311.719640 0 0 0 0 0 0 0-9.071112.78140.95115.70613.5586.626932.0270.4458-9.0711QC'd by "BIOMOL"
Activator0.057321.59260Complete curve; partial efficacy; poor fit-7.24224.95490.832221.5-0.09261.40 0 0 0 0 0 0 1-1.22431.1667-1.32724.134230.183219.819121.766513.8201-1.2243QC'd by "BIOMOL"
Inhibitor18.105652.280721Partial curve; partial efficacy-4.74223.67720.9826-47.78074.5-2.20 0 0 0 0 0 0 0-49.93183.8651.646410.75552.55154.53663.2482-35.6751-49.9318QC'd by "BIOMOL"
Inhibitor22.793673.383320Partial curve; partial efficacy-4.64221.85790.9044-52.409520.9738-2.20 0 0 0 0 0 0 0-41.328131.830419.621231.110913.02038.637315.6851-19.835-41.3281QC'd by "SigmaAldrich"
Activator40.533444.51110Single point of activity-4.39224.95490.643848.54214.030931 0 0 0 0 0 0 045.288229.66648.6048.8809-7.159525.2792.32966.138745.2882QC'd by "SigmaAldrich"
Activator40.533444.63340Single point of activity-4.39224.95490.731647.11612.482730 0 0 0 0 0 0 046.30267.4755-0.75819.27525.209310.4838-1.83621.18346.3026QC'd by "BIOMOL"
Inactive04-0.5052-7.6408-15.7325-0.3027-1.2325-21.3639-9.9587-7.7655-0.5052QC'd by "BIOMOL"
Inactive04-12.3719-13.0834-12.0648-10.9788-16.5816-4.45632.3382-18.163-12.3719QC'd by "NIEHS"
Inhibitor28.695494.188640Partial curve; high efficacy-4.54223.990.9769-86.68867.5-2.10 0 0 0 0 0 0 0-81.40725.66564.976614.47514.160.761214.9064-28.9281-81.4072QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_WT
Protocol: The day before screening, RN4220 was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the Hewlett Packard D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter).
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced WT survival if Z-score for both replicates <= -3 and absorbance for both replicates <= 0.18. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_WT_AAbsorbance_WT_BZ-score WT_AZ-score WT_BPercent Inhibition_WT_APercent Inhibition_WT_B
0.7370.747-1.624235685-1.0789525314.234071413.85068762
0.7480.834-1.4382629330.33116364814.991762772.84634982
0.8350.8340.0326124740.3311636482.922049772.84634982
0.7920.828-0.6943719230.2339142568.8875401023.68971273
0.9390.8961.7909003161.336074027-11.50611289-5.868400246
0.8210.844-0.204080120.4932459674.8643024361.440744971
0.8110.872-0.3731462590.9470764616.25162577-2.494948608
0.8230.872-0.1702668930.9470764614.58683777-2.494948608
0.7990.862-0.5760256250.7849941427.916413769-1.089343758
0.8480.8940.2523984541.3036575631.118529437-5.587279276
0.8410.8920.1340521571.2712410992.08965577-5.306158306
0.8660.8620.5567175040.784994142-1.378652562-1.089343758
0.8760.8650.7257836430.833618837-2.765975895-1.511025213
0.8370.8680.0664257020.8822435332.644585104-1.932706668
0.8380.8630.0833323160.8012023732.50585277-1.229904243
0.8120.844-0.3562396450.4932459676.1128934361.440744971
0.8150.877-0.3055198041.028117625.696696436-3.197751032
0.8650.8950.539810891.319865795-1.239920229-5.727839761
0.8310.88-0.0350139821.0767423163.476979103-3.619432487
0.8440.8450.1847719990.5094541991.673458771.300184486
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Cellular tumor antigen p53
External ID: HMS1485
Protocol: Prior to screening, HeLa cells were transduced with a lentivirus carrying the vector PHAGE-N CMVt N-RIG3 p53(R273C) encoding constitutively expressed SGFP2 fused to histone 2B and mRuby-p53(R273C). Following transduction, the cells were selected using neomycin and fluorescent activated cell sorting. The day before the compound treatment, cells were plated (750 cells/well) in a final volume of 30 L/well of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum using a Thermo Combi. Plates were spun for 45 s at 500 rpm and incubated overnight (~24 h) at 37 degrees C, 5% CO2.

On the day of the screening, 33 nL of each compound was transferred to assay wells via a custom pin-transfer workstation. Additionally, 33 nL of positive (Velcade 300 M) and negative (DMSO 100%) controls were transferred to each plate into the corresponding columns that did not contain experimental compounds. For every compound library plate, there were two daughter plates (A and B). Plates were stacked 5 high, covered with lids, and incubated at 37 degrees C for 24h and 48h.

Assay plates were read using an Acumen Laser Scanning Cytometer 24h and 48h after compound treatment, using the following settings: For SGFP2 (channel 2), the 488 nm laser was used, with 6 mW output, 600 voltage gain and sensitivity threshold at 1; and for mRuby (channel 3), the 561 nm laser was used, with 8 mW output, 600 voltage gain and sensitivity threshold at 1.
Comment: Total nuclei and %p53 positive was calculated for all wells at 24 and 48h using the Cellista software. Percentage of p53 positive cells values were normalized to the positive and negative controls to determine a normalized percent of p53 activation. This was done on a per plate basis. The proteasome inhibitor Velcade (Adipogen, AG-CR1-3602-M005) at 330 nM was used as positive control while only the vehicle (DMSO, Sigma, D8418, 0.1% final concentration) was used as negative control. From these values the following normalized values were calculated (for both 24h and 48h): Normalized total nuclei = (total nuclei in experimental well / plate average negative control total nuclei) * 100. Normalized %p53 positive = (%p53 positive in experimental well - plate average negative control %p53 positive cells) / (plate average positive control %p53 positive cells - plate average negative control %p53 positive cells) * 100.

Based on the normalized percent p53 positive values, a compound was considered active when replicate average normalized % p53 positive cells > 50% for either or both time points. Activity scores were based on the replicate average normalized %p53 positive cells at 24hr. Values less than 0 were set to 0, and values > 100 were set to 100 (100% activity). Compounds with an activity score > 50 were considered active; some compounds were scored active despite having an activity score < 50 since % p53 positive cells was > 50% only at 48hr.

The average normalized total nuclei values were categorized as:
Very Low: x < 25%
Low: 25% < X > 50%
Medium: 50% < X > 75%
High: x < 75%

The average normalized % of p53 positive cells values were categorized as:
Low: x < 25%
Medium: 25% < X > 50%
Strong: 50% < X > 75%
Very Strong: x < 75%

Compounds that scored as strong or very strong in this classification (at either time point) were selected for follow up.
TotalNuclei_24h_A%Pos_24h_ATotalNuclei_24h_B%Pos_24h_BTotalNuclei_48h_A%Pos_48h_ATotalNuclei_48h_B%Pos_48h_BTotalNuclei_Norm_A_24h%Pos_Norm_A_24hTotalNuclei_Norm_B_24h%Pos_Norm_B_24hTotalNuclei_Norm_A_48h%Pos_Norm_A_48hTotalNuclei_Norm_B_48h%Pos_Norm_B_48hAvg_TotalNuclei_Norm_24hAvg_%Pos_Norm_24hAvg_TotalNuclei_Norm_48hAvg_%Pos_Norm_48hViability 24hViability 48hHit 24hHit 48hMolar Concentration
12080.16612330.32415340.065215670.128107.52413010.014207932114.25262060.301056209111.5408212-0.200936304115.8595194-0.078440722110.88837530.15763207113.7001703-0.139688513HighHighLowLow123 uM
12780.078211730.34116440.30415250.262113.754833-0.105094533108.69288240.324276435119.53918520.073652809112.7541590.076453966111.22385770.109590951116.14667210.075053388HighHighLowLow41 uM
11910.33612510.2414840.13515530.258106.01095940.245203592115.92054210.186320973107.9052012-0.120675332114.82439930.071830244110.96575070.215762282111.3648002-0.024422544HighHighLowLow13.7 uM
12350.0811129015390.06514630.273109.9274012-0.101289898104.615741-0.141493985111.9043832-0.201166278108.17005550.089169202107.2715711-0.121391942110.0372193-0.055998538HighHighLowLow4.6 uM
12740.078511270.17716430.36514100.213113.3987928-0.104686893104.43041640.100269547119.46647280.143794919104.25138630.019813371108.9146046-0.002208673111.85892950.081804145HighHighLowLow1.5 uM
12120118401575013830.0723107.8801702-0.211352536109.7121677-0.141493985114.5220296-0.27590787102.2550832-0.142826051108.796169-0.176423261108.3885564-0.209366961HighHighLowLow500 nM
123201268013610.073514110.142109.6603711-0.211352536117.4958012-0.14149398598.96157604-0.191392377104.3253235-0.062257695113.5780861-0.176423261101.6434498-0.126825036HighHighLowLow10 mM
11450.087311640.25814730.067914790.203101.9164975-0.092729471107.85892160.210907095107.1053648-0.197831653109.35304990.008254066104.88770950.059088812108.2292074-0.094788793HighHighLowLow3.333 mM
13740.29111470.087216030.37414470.0691122.29979690.184057682106.2836625-0.022387884116.55797680.154143755106.987061-0.146525029114.29172970.080834899111.77251890.003809363HighHighLowLow1.111 mM
12080.1661215014450.13815520.0644107.52413010.014207932112.5846991-0.141493985105.0694176-0.11722572114.7504621-0.151957902110.0544146-0.063643027109.9099399-0.134591811HighHighLowLow370 uM
11270.17712080.24814480.20713550.221100.31431670.02915471111.9360630.197248139105.2875548-0.037884645100.18484290.029060815106.12518990.113201424102.7361989-0.004411915HighHighLowLow123 uM
12640.079111330.088314210.49313650.147112.5086924-0.103871615104.9863902-0.020885398103.324320.290978363100.9242144-0.056478042108.7475413-0.062378506102.12426720.11725016HighHighLowLow41 uM
13160.0761210015700.31814720.204117.1372145-0.108083888112.1213876-0.141493985114.15846760.089750998108.83548980.009409997114.6293011-0.124788937111.49697870.049580497HighHighLowLow13.7 uM
13470.14812700.078715580.25715460.259119.8965258-0.010250432117.6811258-0.033997997113.28591880.019608888114.30683920.072986175118.7888258-0.022124215113.7963790.046297531HighHighLowLow4.6 uM
12110.16511810.33914800.2714510.276107.79116020.012849134109.43418080.321544644107.61435160.034557207107.28280960.092636994108.61267050.167196889107.44858060.0635971HighHighLowLow1.5 uM
11920.083912690.078814800.2715360.13106.0999694-0.097349384117.5884635-0.033861407107.61435160.034557207113.5674677-0.076128861111.8442165-0.065605396110.5909096-0.020785827HighHighLowLow500 nM
1241011680.17114890.26914690.136110.4614614-0.211352536108.22957090.092074173108.26876320.033407336108.6136784-0.069193278109.3455161-0.059639182108.4412208-0.017892971HighHighLowLow10 mM
11390.08781049013460.29713270.226101.3824372-0.09205007297.2027567-0.14149398597.870890050.06560371498.114602590.03484046899.29259695-0.11677202997.992746320.050222091HighHighLowLow3.333 mM
11890.084111490.08714700.3414030.214105.8329393-0.097077625106.4689871-0.022661063106.88722760.115048152103.73382620.020969302106.1509632-0.059869344105.31052690.068008727HighHighLowLow1.111 mM
1239011330.26514760.20313910.431110.2834414-0.211352536104.98639020.220468365107.323502-0.042484127102.84658040.271806223107.63491580.004557914105.08504120.114661048HighHighLowLow370 uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1364-MLP_ugtP
Protocol: The day before screening, RN4220 ugtP was grown overnight (16-18 h) in sterile-filtered tryptic soy broth (TSB) at 30 degrees C with shaking.

On the day of screening, columns 1-24 of assay plates (Corning 3710, clear) were prefilled with 30 uL of TSB using the Combi. Next, 100 nL of each compound was pin-transferred to each plate. For every compound library plate, there were two daughter plates (A & B). Overnight cultures were diluted 625x into TSB. 50 uL of the diluted cultures were added to columns 1-24 of the corresponding assay plates. Wells in column 2 contained only medium (with culture) and served as the negative controls. Positive control (0.8 uL of erythromycin, 10 ug/mL) was added to column 1 using the D300. Final assay well volume was 80 uL. Plates were spun down and stacked 5 high, covered with lids (Corning 3009), and incubated at 30 degrees C overnight (~16 h).

The following day, assay plates were removed from the incubator and cell density quantitated using a PerkinElmer EnVision (600 nm filter). Library plates were screened in duplicate, with both assay plates in a given set prepared on the same day.
Comment: Z-scores were calculated for every well based on plate average and standard deviation of experimental well absorbance (OD600). Wells were considered active for reduced ugtP survival if Z-score for both replicates < -3 and absorbance for both replicates <= 0.15. Percent inhibition was calculated by subtracting well absorbance from negative control plate average absorbance, dividing by the difference between plate negative and positive control plate average absorbance, and multiplying by 100. The replicate values were then averaged to determine activity scores. Resulting values > 100 were set to 100 and < 0 were set to 0, where 100 = 100% activity.
Absorbance_ugtP_AAbsorbance_ugtP_BZ-score ugtP_AZ-score ugtP_BPercent Inhibition_ugtP_APercent Inhibition_ugtP_B
0.5140.537-1.229512579-0.52346704814.474576278.463841548
0.5470.588-0.7679522420.1914626568.508474576-0.932749885
0.6270.6070.3509819090.457809016-5.95480226-4.433440811
0.6140.6060.1691551090.443790786-3.604519774-4.24919392
0.6040.5740.02928834-0.004792557-1.7966101691.646706587
0.5640.55-0.530178735-0.3412300655.4350282496.068631967
0.6150.5740.183141786-0.004792557-3.7853107341.646706587
0.6170.6130.211115140.541918393-4.146892655-5.538922156
0.6010.604-0.012671690.415754327-1.254237288-3.880700138
0.7040.71.4279560291.761504358-19.87570621-21.56840166
0.6240.6150.3090218780.569954852-5.412429379-5.907415937
0.6450.6110.6027420930.513881934-9.209039548-5.170428374
0.5440.599-0.8099122730.3456631810.06359478-2.989036353
0.5620.617-0.5581520890.5979913116.850384916-6.312752452
0.5490.594-0.7399788880.2755720339.171036483-2.065781881
0.560.63-0.5861254420.7802282947.207408234-8.71321408
0.5690.545-0.46024535-0.4113212125.6008033026.982111945
0.5350.554-0.935792365-0.28515714711.670199715.320253895
0.5170.525-1.187552548-0.69168580214.8834095710.67512983
0.5130.534-1.243499256-0.56552173615.597456219.013271783
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:N/A
External ID: HMS1149-MLP
Protocol: A 558 bp region upstream of hspX was PCR amplified and cloned upstream of the GFP-mut2 (Cormack et al., 1996). This construct was cloned into a modified version of the replicating plasmid pSE100 and transformed into CDC1551 to generate CDC1551(hspX'::GFP).

The M. tuberculosis CDC 1551 (hspX'::GFP) fluorescent biosensor was grown in pH 7.0 Middlebrook 7H9 medium to mid- to late-log phase. Black-walled, clear-bottom, tissue-culture treated 384-well microtiter plates (Corning #3712) were filled with 25 uL of buffered pH 7.0 7H9 medium using a Matrix Combi. 100 nL of compound was then transferred to each well via stainless steel pin array. Plates were manually sealed with DMSO-resistant aluminum seals and frozen at -80C until they were ready to be screened. The cultures were re-suspended in pH 7.0 7H9 and 25 uL was dispensed into each well of the 384-well assay plates already containing the perturbator utilizing a Cy-Bio Selma liquid handler robot to an OD595 of 0.05. The plates were then placed in a Ziploc bag with a moistened paper towel (to limit evaporation) and incubated for 6 days at 37C. Fluorescence and optical density (OD) readings were made on an EnSpire plate reader (Perkin Elmer, Inc.) at excitation and emission wavelengths of 488 and 509 nm as a top read, with the OD being taken at 595 nm as a bottom read.

The ~328,633 compound library was arrayed into black-walled, clear-bottom tissue-culture treated 384-well microtiter plates (Corning #3712) by pin transfer (100 nL), containing 25 uL of buffered pH 7.0 7H9 medium. In a previous screen utilizing the same compound library and screening method, four random compound plates were screened in duplicate to observe variation in hit robustness across plates and method. The result was that the duplicate plates did not vary in a statistically significant manner and due to the high volume of compounds to be screened (~328,633), replicates were not utilized.

Negative control: DMSO, 0.1% final concentration in buffered pH 7.0 7H9 in column 2 or column 23 of each plate

Positive control: 0.3 uM Rifampicin final concentration in buffered pH 7.0 7H9 in column 1 or column 24 of each plate
Comment: Analysis methods:
To calculate normalized fluorescence percent inhibition, plate average negative control fluorescence intensity (based on all plates within a screening run) was subtracted from well fluorescence intensity, divided by the difference between plate negative and positive control average fluorescence intensity (based on all plates within a screening run), and multiplied by 100. To calculate normalized growth inhibition, plate average negative control absorbance (based on all plates within a screening run) was subtracted from well absorbance, divided by the difference between plate negative and positive control average absorbance (based on all plates within a screening run), and multiplied by 100. Normalized fluorescence percent inhibition was divided by normalized growth inhibition to calculate a ratio. Wells were considered active if growth was not greatly decreased and showed either a 3-fold selectivity fluorescence to growth inhibition ratio (with 35-45% fluorescence inhibition) or a 1.5-fold selectivity fluorescence to growth inhibition ratio (with > 45% fluorescence inhibition). These compounds may be directly or indirectly inhibiting DosRS signaling. Wells were considered general inhibitors of M. tuberculosis growth if both fluorescence and growth inhibition > 50%. Activity scores were scaled from 100 to 0 and derived from normalized fluorescence percent inhibition, with 100 (or > 100) = 100% inhibition and 0 (or < 0) = no inhibition.
FluorescenceAbsorbanceRatioNormalized Fluorescence InhibitionNormalized Growth InhibitionNormalized FI:GI RatioGeneral Inhibition
361550.2851268608.990745.250731.71228
367210.2811306807.519896.929291.08523
388660.291340211.945723.152540.617191
373140.281332645.978877.348930.81357
359490.2791288499.526077.768571.22623
359210.2871251609.598834.411462.17589
362680.2931237828.697091.893624.59283
392470.321226470.955621-9.43663-0.101267
386200.2861350352.584994.83110.535074
373510.2841315185.882725.670371.03745
380970.2831346183.94416.090010.647635
378520.2951283124.580781.054344.34468
372680.2981250606.09841-0.204574-29.8103
396530.284139623-0.09944285.67037-0.0175373
377440.2931288194.861441.893622.56727
377300.2871314634.897824.411461.11025
391230.3011299771.27786-1.46349-0.873157
366370.2871276557.738184.411461.75411
405660.327124055-2.47204-12.37410.199775
393340.2861375310.7295364.83110.151008